As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.
Angie Franks, Kalderos
Advertisement
Articles by Angie Franks, Kalderos
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Novartis Expands US Footprint With New Radioligand Therapy Manufacturing Facility in California
2
Your DSCSA Responsibilities
3
Data Quality and Skill Gaps Pose Major Barriers to AI Adoption
4
Arsenal Capital Partners Completes ThermoSafe Acquisition
5
